Premium
Anti apoptotic role of CCR9 in prostate cancer
Author(s) -
Sharma Praveen Kumar,
Singh Rajesh,
Lillard James W.,
Chung Leland W.K.,
Grizzle William E.,
Singh Shailesh
Publication year - 2008
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.22.1_supplement.1079.16
Subject(s) - lncap , prostate cancer , cancer research , apoptosis , etoposide , doxorubicin , medicine , pi3k/akt/mtor pathway , metastasis , cancer , chemotherapy , pharmacology , chemistry , biochemistry
Limited treatment choices are available for the PCa patients with hormone refractory and metastatic disease. One of the better choices for treating hormone refractory metastatic disease is chemotherapy. Unfortunately better efficacy of these therapeutic modalities cannot be achieved due to the indolent nature of PCa with a very low rate of apoptosis and proliferation. We have recently shown that PCa cells (PC3, LNCaP and C4‐2b) express CCR9 and play significant role in cancer cell migration and invasion in vitro. Here we show that, CCR9‐mediated activation of PI3K/AKT pathway, which inhibits the activation of caspase‐3 and ‐9. Apoptosis induced by Etoposide or Doxorubicin in PCa cells was significantly inhibited after CCL25 treatment and further achieved after blocking CCR9‐CCL25 interaction with anti‐CCR9 monoclonal antibody. These results suggest that CCR9‐mediated cell signals provide protection against drug‐induced apoptosis. Therefore, inhibition of this axis will increase the efficacy of therapeutics for prostate cancer.